Licogliflozin
1291094-73-9
≥98%
416
LIK066; (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
- Data sheet: View or download
- MSDS: View or download
Licogliflozin is a dual inhibitor of Sodium/glucose cotransporters SGLT1 and SGLT2 with a higher selectivity for SGLT2 (in vitro IC₅₀ values of 20.6 and 0.58 nM, respectively). It causes a reduction in body weight from baseline versus placebo after 24 weeks (50 mg twice daily). However, the percent decreases were numerically small (<5%). Higher doses of licogliflozin also reduce waist circumference, fasting plasma glucose, hemoglobin A1c (HbA1c), systolic blood pressure and triglycerides. It increases HDL cholesterol and 24‐hour urinary glucose excretion.
-20°C
